Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, extending insulin secretion and decreasing glucagon levels in a glucose-dependent manner. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/fecal route rather than the kidneys.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age).
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required regardless of degree of renal impairment (including end-stage renal disease).
* **Hepatic Impairment:** No dose adjustment required in patients with hepatic impairment.
* **CYP3A4/P-gp Inducers:** If a strong inducer (e.g., rifampin) is co-administered, therapeutic effect of linagliptin may be reduced.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis (rare), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4 or P-glycoprotein inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease linagliptin concentrations. Consider alternative antidiabetic therapy if glycemic control is inadequate.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; a lower dose of the secretagogue or insulin may be required.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months) and fasting plasma glucose.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain radiating to the back.
* **Skin:** Assess for new-onset blistering or erosions suggestive of bullous pemphigoid.
## Clinical Pearls
* Linagliptin is weight-neutral and has a low intrinsic risk of hypoglycemia when used as monotherapy.
* It is the only DPP-4 inhibitor that does not typically require dosage adjustments for renal function, making it a convenient option for patients with chronic kidney disease.
* Can be taken with or without food.
* If a dose is missed, it should be taken as soon as the patient remembers that day; do not take double doses.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and drug interactions against the most current FDA-approved prescribing information, institutional protocols, or clinical decision support software before prescribing or administering medication.
